Board of Directors

Jeffrey J. Kraws

Chairman

Mr. Kraws was appointed independent, non-executive Chairman of Synthetic Biologics' Board in May 2012. Since 2003, Mr. Kraws has served as Chief Executive Officer and co-founder of Crystal Research Associates, and since February 2012, he has served as partner and co-founder of TopHat Capital, LLC. Well known and respected on Wall Street, Mr. Kraws has received some of the most prestigious awards in the industry. Among other awards, he was given a “5-Star Rating” in 2001 by Zacks and was ranked the number one analyst among all pharmaceutical analysts for stock performance in 2001 by Starmine.com. Prior to founding Crystal Research Associates, Mr. Kraws served as co-president of The Investor Relations Group (IRG), a firm representing primarily under-followed, small-capitalization companies. Previously, Mr. Kraws served as a managing director of healthcare research for Ryan Beck & Co. and as director of research/senior pharmaceutical analyst and managing director at Gruntal & Co., LLC (prior to its merger with Ryan Beck & Company). Mr. Kraws served as managing director of the healthcare research group and senior pharmaceutical analyst at First Union Securities (formerly EVEREN Securities); as senior U.S. pharmaceutical analyst for the Swedish-Swiss conglomerate Asea Brown Boveri; and as managing director and president of the Brokerage/Investment Banking operation of ABB Aros Securities, Inc. He also served as senior pharmaceutical analyst at Nationsbanc Montgomery Securities, BT Alex Brown & Sons, and Buckingham Research. Mr. Kraws also has industry experience, having been responsible for competitive analysis within the treasury group at Bristol-Myers-Squibb Company. He holds an MBA from Cornell University and a BS degree from State University of New York-Buffalo.

Committees

Committee Role
Compensation Committee Chair
Audit Committee Member
Nominations Committee Member

Scott L. Tarriff

Director

Mr. Tarriff brings more than 25 years of pharmaceutical experience to Synthetic Biologics. In January 2007, he formed Eagle Pharmaceuticals, Inc., a hospital specialty company focused on developing, distributing and in-licensing injectable IV products. Prior to forming Eagle, Mr. Tarriff served as President, Chief Executive Officer and Director of Par Pharmaceutical Companies, Inc. (NYSE: PRX). During his tenure at Par, he also served as the Executive Vice President of Business and as President and Chief Executive Officer of Par Pharmaceutical, Inc., the company's principal operating subsidiary. Mr. Tarriff joined Par following a 12-year career at Bristol-Meyers Squibb, where he held several positions of increased responsibility in both the brand and generic divisions. He also served as a Director of Clinical Data, Inc., a publicly-traded biopharmaceutical company which was acquired by Forest Laboratories, Inc. in 2011. Mr. Tarriff received an MBA from Rider College and an undergraduate degree from Pennsylvania State University.

Committees

Committee Role
Nominations Committee Chair
Audit Committee Member
Compensation Committee Member

Jeffrey Wolf, JD

Director

Mr. Wolf has substantial experience in creating, financing, nurturing and growing new ventures based upon breakthrough research and technology. In 2008, he founded Heat Biologics, Inc., a publicly traded company engaged in the research and development of drugs focused on cambating cancer and other diseases, and has served as its Chief Executive Officer since April 2010. Mr. Wolf is the founding partner of Seed-One Ventures, LLC, a venture capital group focused on seed-stage technology-based investments. Mr. Wolf has been a founder of Elusys Therapeutics, Inc., an antibody-based therapeutic company, Tyrx Pharma, Inc., a biopolymer-based company, Sensatex, Inc., a medical device company and Generation Mobile, Inc. a telecommunications company. Prior to founding Seed-One Ventures, Mr. Wolf served as the Managing Director of The Castle Group, Ltd., a biomedical venture capital firm. At both organizations, Mr. Wolf was responsible for supervising the formation and funding of new technology, biomedical, and service oriented ventures. Mr. Wolf currently sits on the board of Heat Biologics, Inc. (NASDAQ: HTBX), Elusys Therapeutics and Netli, Inc. Mr. Wolf received an MBA from Stanford Business School, a JD from New York University School of Law and a BA with honors in Economics from the University of Chicago.

Committees

Committee Role
Audit Committee Chair
Compensation Committee Member
Nominations Committee Member